Alzumab L 100mg Injection contains an active component as Itolizumab. It is a monoclonal antibody used to treat certain autoimmune conditions, particularly moderate to severe psoriasis and rheumatoid arthritis. Monoclonal antibodies are synthetic proteins designed to mimic the immune system's ability to target specific substances in the body. This medication was originally developed in Cuba and has been approved for moderate to severe plaque psoriasis. It has shown promising results in studies for rheumatoid arthritis as well. This medication has generally shown good tolerability in clinical trials. Common side effects are usually mild to moderate, including infusion-related reactions, headache, dizziness, and mild gastrointestinal symptoms. Serious adverse events are relatively rare. Individuals with known hypersensitivity or severe allergic reactions to Alzumab L 100mg Injection or any of its components should avoid its use. This medication may impact the immune system, increasing the risk of infections. Patients with active infections may need to have their condition managed and the infection resolved before starting treatment. Live vaccines should be avoided during treatment since they may interfere with effectiveness. Patients should consult their healthcare provider about appropriate vaccination schedules. Individuals with certain pre-existing conditions, such as immunosuppression or a history of severe infections, may require caution due to the potential risk of further immunosuppression.